EUVIMEDOpdag EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access · CC BY-NC-ND 4.0

Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases

Laura A Voss, Rebekah J Nevel, Jennifer A Wambach, Lawrence M Nogee, Robin R Deterding, Alicia M Casey, Michael G O'Connor, Daniel I Craven, Jane B Taylor, Gail H Deutsch, Jade B Tam-Williams, Lea C Steffes and 12 more

Pediatric Pulmonology · 2025-04 · 60 (4)

DOI: 10.1002/ppul.71073 ↗

At a glance

Multizentrische Studie in Pediatric Pulmonology, 2025-04. Written by Laura A Voss and 23 co-authors. Institution: Pediatrics, Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Genetic Testing, Lung Diseases, Interstitial. Cited 9 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NHLBI NIH HHS, NCATS NIH HHS, Financial support was provided by the National Institutes of Health, the Children's Discovery Institute at St. Louis Children's Hospital, and the Children's Ho….

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Childhood interstitial and diffuse lung diseases (chILD) comprise a diverse group of rare disorders. Identifying the underlying cause is crucial for treatment, prognosis, and estimating recurrence risk. The objective of this study was to assess the utilization of genetic testing for subjects enrolled in the United States National Registry for ChILD, a multicenter observational study.

Methods

Genetic data from participating sites were reviewed and analyzed in relationship to clinical characteristics.

Results

Of 609 children enrolled from 22 centers, genetic testing was performed for 55.5% ( n = 338). Genetic testing results were positive (diagnostic) for 22.8% ( n = 77), negative for 60.7% ( n = 205), and uncertain for 16.6% ( n = 56). Most testing was performed through gene panels (55.9%), followed by exome sequencing (ES) or whole genome sequencing (WGS) (26.9%), single gene testing (24.6%), and/or chromosomal microarray (11.8%). For participants with positive (diagnostic) genetic testing results, the majority were diagnosed through gene panel (33.8%; n = 26) or single gene testing (32.5%; n = 25). The most common diagnosis confirmed by genetic testing was SFTPC ‐associated surfactant metabolism dysfunction. Of the 59 subjects with unclassified ILD, only 22% ( n = 13) had undergone ES or WGS, 61% ( n = 36) had received panel testing, and 27% ( n = 16) did not have any genetic testing reported.

Conclusion

The utilization of genetic testing has been variable in infants and children enrolled in the ChILD Registry. Additional efforts are needed to develop genetic testing recommendations for children with suspected ILD. Furthermore, there is opportunity for broader utilization of ES/WGS and genetic discovery for children with lung disease of unclear etiology.

Subjects

MeSH terms (MEDLINE)

Genetic TestingLung Diseases, InterstitialHumansRegistriesChildUnited StatesMaleFemaleChild, PreschoolInfantAdolescentExome Sequencing

Author keywords

childhood interstitial lung disease (chILD)genetic testingrare lung diseases

Authors and institutions

  • Pediatrics, Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA.
  • Pediatrics, Division of Pediatric Pulmonary Medicine, University of Missouri School of Medicine and Children's Hospital, Columbia, Missouri, USA.
  • Division of Newborn Medicine, Edward Mallinckrodt Department of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Pediatrics, Section of Pediatric Pulmonary and Sleep Medicine, University of Colorado Denver, Aurora, Colorado, USA.

Funding

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • Financial support was provided by the National Institutes of Health, the Children's Discovery Institute at St. Louis Children's Hospital, and the Children's Ho…
  • National Institutes of Health

Cite

APA

Voss, L. A., Nevel, R. J., Wambach, J. A., Nogee, L. M., Deterding, R. R., Casey, A. M., O'Connor, M. G., Craven, D. I., Taylor, J. B., Deutsch, G. H., Tam-Williams, J. B., Steffes, L. C., Brennan, S. K., Santiago, M. T., Sadreameli, S. C., Heras, A. F., Powers, M. R., Popova, A. P., Bansal, M., …, & ChILD Registry Collaborative (2025). Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases. Pediatric Pulmonology, 60(4). https://doi.org/10.1002/ppul.71073

Vancouver

Voss LA, Nevel RJ, Wambach JA, Nogee LM, Deterding RR, Casey AM, et al. Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases. Pediatric Pulmonology. 2025;60(4). doi:10.1002/ppul.71073

BibTeX
@article{Voss2025,
  author = {Voss, Laura A and Nevel, Rebekah J and Wambach, Jennifer A and Nogee, Lawrence M and Deterding, Robin R and Casey, Alicia M and O'Connor, Michael G and Craven, Daniel I and Taylor, Jane B and Deutsch, Gail H and Tam-Williams, Jade B and Steffes, Lea C and Brennan, Steven K and Santiago, Maria T and Sadreameli, Sara C and Heras, Andrea F and Powers, Michael R and Popova, Antonia P and Bansal, Manvi and Hamvas, Aaron and Gower, William A and Urrego, Fernando and Young, Lisa R and ChILD Registry Collaborative, ChILD Registry Collaborative},
  title = {Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases},
  journal = {Pediatric Pulmonology},
  year = {2025},
  volume = {60},
  number = {4},
  doi = {10.1002/ppul.71073}
}
Start for free →